Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2

Cancer immunotherapies under development have generally focused on either stimulating T-cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Cell
Autores principales: Zhu, Eric F., Gai, Shuning A., Opel, Cary F., Kwan, Byron H., Surana, Rishi, Mihm, Martin C., Kauke, Monique J., Moynihan, Kelly D., Angelini, Alessandro, Williams, Robert T., Stephan, Matthias T., Kim, Jacob S., Yaffe, Michael B., Irvine, Darrell J., Weiner, Louis M., Dranoff, Glenn, Wittrup, K. Dane
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4398916/
https://ncbi.nlm.nih.gov/pubmed/25873172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2015.03.004
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares